Purchase Order 75F40123P00260

<p>The Food and Drug Administration awarded a purchase order to Illumina, Inc. for preventive maintenance service for two Illumina MiSeq instruments, with a ceiling value of $58,464.00 and an award date of April 13, 2022. Place of performance is Jefferson, Arkansas. The order carries no set-aside and firm fixed pricing. Ultimate completion date is July 19, 2027.</p>

<p>The Food and Drug Administration awarded a purchase order to Illumina, Inc. for a MiSeq Silver Support Plan with a ceiling value of $388,924.75, effective through November 25, 2024, and dated June 18, 2019. Work is performed in Silver Spring, Maryland. The order is firm fixed price with no set-aside applied.</p>

<p>The Food and Drug Administration awarded a purchase order to Illumina, Inc. for $13,507.20 on December 17, 2021 for service contract support of a MiSeq instrument, with an ultimate completion date of December 19, 2022. The order carries a Total Small Business set-aside. Work is performed in Denver, Colorado. The purchase order is firm fixed price.</p>

The Food and Drug Administration awarded a purchase order to Illumina, Inc. for MiSeq Silver Support Plans covering preventative maintenance for five MiSeq instruments in the Center for Food and Applied Nutrition, with a ceiling value of $425,145.40 and an award date of August 31, 2024. The order is firm fixed price with no set-aside. Performance occurs in Laurel, Maryland through September 29, 2029, comprising a 12-month base period and four 12-month option periods. The procurement proceeded as...

The Department of Health and Human Services' Food and Drug Administration awarded a firm fixed-price purchase order to Illumina, Inc., a manufacturer of sequencing and array-based solutions, to provide a MiSeq System for $95,931.00. The MiSeq System is an integrated system for automated generation of DNA clonal clusters, sequencing, and primary and secondary analysis. The award was made on February 28, 2020 with a completion date of March 12, 2021. There was no set-aside used for this...

<p>The Food and Drug Administration issued a delivery order to Illumina, Inc. on August 25, 2016, for MiSeq reagent kits with a ceiling value of $8,571.86. Place of performance is San Diego, CA 92121. The order was scheduled for ultimate completion on September 13, 2017, and was priced on a firm fixed-price basis with no set-aside applied.</p>

The Department of Health and Human Services Food and Drug Administration awarded a $67,963.80 firm fixed price purchase order to Illumina, Inc. for corrective, remedial, repair, and preventive maintenance services for Illumina's MiSeq sequencing systems. The contract has a period of performance through February 28, 2025 and was awarded on December 12, 2019. No set-aside designation was used for this award to support the FDA's medical device evaluation programs through ongoing maintenance and...

The Food and Drug Administration awarded a $996,000 firm fixed-price delivery order to Illumina, Inc. for a MiSeq Sequencer and associated reagents on September 15, 2014, with an ultimate completion date of September 13, 2017. The award was issued to the San Diego-based biotechnology company without set-aside designation, reflecting Illumina's specialized position as the primary provider of next-generation DNA and RNA sequencing technologies to federal agencies. The delivery order procures...

The Department of Health and Human Services Food and Drug Administration awarded a $474,577.44 firm fixed price purchase order for preventive maintenance and repair services for Illumina, Inc.'s MiSeq DNA sequencing systems. The contract was awarded on December 4, 2017 with a completion date of December 5, 2019. Illumina is a manufacturer of a range of genetic and genomic analysis instruments and reagents, and has provided similar products and services to support research and diagnostics at...

This is a firm fixed price delivery order awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based analytical instruments and reagents for genetic and genomic analysis. The contract is for the provision of a MiSeq sequencing instrument to support the FDA's genomic sequencing and analysis work, with a ceiling value of $81,810. The contract is not associated with a set-aside or a larger contract vehicle, and there is no indication of any...